2026-01-15 - Analysis Report
**Report**

### Company Overview
Amgen Inc., a biotechnology company.

### Return Rate Comparison
- Return rate of review stock (AMGN): 67.85%
- Return rate of comparison stock (S&P 500, VOO): 93.94%
- Divergence in cumulative return on the last day of the data: -25.09%
- Relative divergence: 27.80%

### Analysis of Provided Content
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 14.0% | 14.6% | 11.0% | 1.10 | 105.7B |
| 2017-2019  | 41.0% | 12.4% | 24.0% | 0.90 | 130.9B |
| 2018-2020  | 8.0% | 17.7% | -13.0% | 0.80 | 124.8B |
| 2019-2021  | 15.0% | 17.7% | -28.0% | 0.80 | 122.1B |
| 2020-2022  | 15.0% | 15.5% | 17.0% | 0.60 | 142.6B |
| 2021-2023  | 19.0% | 15.3% | 19.0% | 0.40 | 156.3B |
| 2022-2024  | 12.0% | 21.0% | -8.0% | 0.40 | 141.5B |
| 2023-2025  | 38.0% | 21.0% | -24.0% | 0.50 | 177.7B |

### Recent Stock Price Fluctuations
| Metric        | Value |
|---------------|-------|
| Close price   | $324.30
| 5-day SMA     | $329.54
| 20-day SMA    | $328.57
| 60-day SMA    | $323.08
| Last-market   | $327.00

### Analysis of RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence, Expected_Return
- Market Risk Indicator (MRI): 0.70
- RSI: 43.52
- PPO: -0.20
- Hybrid Signal: Buy
- Risk Level: Medium
- Recent (20 days) relative divergence change: -5.00
- Expected Return (%): -2.50%

### Recent News & Significant Events
- Amgen Inc. (NASDAQ:AMGN) Shares Could Be 49% Below Their Intrinsic Value Estimate.
- Amgen Inc $AMGN Shares Acquired by Global Wealth Management Investment Advisory Inc.
- Representative Julia Letlow Just Disclosed New Stock Trades.
- Amgen Stock (AMGN) Falls despite Obesity Drug Update.
- BofA Securities raises Amgen stock price target to $304 on valuation shift.

### Analyst Opinions
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.41 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): $331.59 / $425.00 / $180.00

### Recent Earnings Analysis
| Date | EPS | Revenue |
|----|----|----|
| 2025-11-05 | 5.98 | $9.56B |
| 2025-08-06 | 2.66 | $9.18B |
| 2025-05-02 | 3.22 | $8.15B |
| 2024-10-31 | 5.27 | $8.50B |
| 2025-11-05 | 5.27 | $8.50B |

### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $9.56B | 67.75% |
| 2025-06-30 | $9.18B | 67.20% |
| 2025-03-31 | $8.15B | 63.58% |
| 2024-12-31 | $9.09B | 65.75% |
| 2024-09-30 | $8.50B | 61.07% |

### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $9.62B | 33.43% |
| 2025-06-30 | $7.43B | 19.28% |
| 2025-03-31 | $6.21B | 27.87% |
| 2024-12-31 | $5.88B | 10.67% |
| 2024-09-30 | $7.53B | 37.60% |

### Comprehensive Analysis
The cumulative return of AMGN (67.85%) is lower than that of S&P 500 (93.94%). The divergence in cumulative return is -25.09%. The relative divergence is 27.80%. The recent stock price fluctuations show a slight increase. However, the RSI and PPO indicators suggest a sell signal. The Market Risk Indicator is moderate. The expected return is -2.50%. There are significant recent news and events, including a possible undervaluation and a raise in stock price target. The analyst consensus is Buy, with an average target price of $331.59. The revenue and profitability show a consistent increase. The capital and profitability show an increase in equity and ROE.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.